OncoNetwork

A kind of digital/social media oncology journal. It is an account created to deliver scientific data about oncology to more readers.

[Yakup Ergün @dr_yakupergun]

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival

💫Great article about an argument that will never end.

@JCO_ASCO
https://t.co/XP5PZ2XGpY

[Filippo Montemurro @FilippoMontemu1]

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 https://t.co/l6QlCVpqVN Is there hope for treatment tailoring in HER2 positive metastatic breast cancer? Congrats! Intriguing findings

[Jarushka Naidoo @DrJNaidoo]

Press Release #3

Ph II KN-483 trial Pembro+Chemo improves OS in First-line Mesothelioma ⁦@IFCTlung⁩ ⁦@CDNCancerTrials⁩

Will be interesting to see how this integrates w CM743 (ipi/nivo) & how histologic subtypes factor into tx selection #LCSM https://t.co/uvg0YYEQJT

[Dipesh Uprety MD FACP @DipeshUpretyMD]

In this retrospective study (n=506,889) @JCOOP_ASCO w/ advanced NSCLC
-> 64% pts did not benefit from precision oncology therapy
-> ~50% lost to precision oncology and remaining 29% did not receive appropriate targeted therapy #LCSM @OncoAlert
https://t.co/tTNeqhmBGN

[Nat Lester-Coll, MD @DrLesterColl]

🚨@OncoAlert 15-year outcomes of the landmark ProtecT trial published in @NEJM

Importantly, no treatment complications reported after 10 years

#pcsm #radonc
https://t.co/40NgEhGKAU

[@GynOncJnls @gynoncjnls]

Topotecan plus paclitaxel not superior to cisplatin plus paclitaxel for recurrent/metastatic cervical cancer @SGO_org @IGCSociety @ESGO_society @ASCO @myESMO @OncoAlert @GOG @Gyne_Oncology @acog https://t.co/EikRFqZCg9

[Hassan Aziz, MD, FACS @Sharpknife_Aziz]

Presented my work on resident experience in pancreatic surgery during general surgery residency #ahpba23 #AHPBA23 .

[Patrick Forde @FordePatrick]

With the recent press releases on immunotherapy for surgical lung cancer, watch for CheckMate 816 (neoadj chemo-nivo for 3 doses only) update at #ELCC23 March 30. Dr. @nicogirardcurie will report overall survival at 3 yrs. Two yr follow up looked good, will benefit hold up? #lcsm

[Yakup Ergün @dr_yakupergun]

European Expert Panel Consensus on the Clinical Management of BRAFV600E-Mutant Metastatic Colorectal Cancer

💥Expert opinion on options for treatment sequencing in four representative clinical scenarios👇

@OncoAlert

#ColorectalCancer
https://t.co/DqpCM9Mow6

[Yakup Ergün @dr_yakupergun]

Pembrolizumab Use Among Adults With Diffuse Malignant Peritoneal Mesothelioma

Retrospective
PDL1 +➡️35%
median number of lines prior therapy➡️Two

ORR (19 pts)➡️21%
DCR➡️74%
mPFS➡️4.9 mos

@OncoAlert @JAMANetworkOpen
@michael_offin @connorbgrady

https://t.co/7M3R9sDw3C

[Yakup Ergün @dr_yakupergun]

Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options

An excellent review published in @JCO_ASCO 👇

@OncoAlert
https://t.co/IswYHLn3hl

[Yakup Ergün @dr_yakupergun]

mFOLFIRINOX plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients
(HCRN GI14-198)

FFX/RAM vs FFX
PFS➡️5.6 vs 6.7 mos
OS➡️10.3 vs 9.7 mos

💥The addition of RAM to FFX did not significantly impact PFS or OS

@OncoAlert
https://t.co/uPU5mu3HlL

[Stephen V Liu, MD @StephenVLiu]

Perioperative immunotherapy for resectable NSCLC will be a very crowded space. Press release tells us AEGEAN and KEYNOTE 671 hit their endpoints. Expect a lot of cross-trial comparisons over the next year or two. Ready for the next wave of trials to further refine delivery! #LCSM

[Arndt Vogel @ArndtVogel]

🔥Novel microenvironment-based classification of cholangiocarcinoma with therapeutic implications
@Gut_BMJ
https://t.co/D8k8pvwKUy
👏Great classification with key immunophenotype
correlations -> most iCCA are cold tumors -> we need combinations💊
@EASLedu #LiverTwitter @myESMO

[Arndt Vogel @ArndtVogel]

🔥Regorafenib, Ipilimumab & Nivolumab for MSS #ColonCancer With Prior Chemotherapy
@JAMAOnc
https://t.co/a0iSil4rVm
✅🇺🇸Phs-I 39 pts
👉ORR 27.6%, mPFS 4 mo & mOS 20 mo
❌Responses limited to pts without liver mets
🧐Promising, at least...
@myESMO @OncoAlert

[Ibrahim Halil SAHIN, MD @IbrahimSahinMD1]

✳️Our article on neoadjuvant IO for MMR-D/MSI-H colon and rectal cancer is now out ‼️ @JCOOP_ASCO @OncoAlert @ASCO
✳️Happy this came out in #colorectalcancerawareness month ❗️
👇Here some key points from this article ❗️
https://t.co/SOzCE1ciMS

[Vivek Subbiah, MD @VivekSubbiah]

The abscopal effect in patients with cancer receiving immunotherapy https://t.co/7h2ZXI8tES

[Yakup Ergün @dr_yakupergun]

Osimertinib plus ChT
Exciting data.
Previously, successful results were obtained with the combination of Gefitinib + ChT.
If we can manage the side effects successfully, the combination of Anti-EGFR TKI + ChT seems to be a preferable option.

[Thierry Alcindor, MD, MSc @Thalcin]

What a satisfaction, to be an author on an ⁦@NEJM⁩ paper that will change the management of desmoid tumors! https://t.co/YNlLTV6Jdm

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

Out in EJC the full 📄 of the Japan Ph2 trial of Osimertinib in combo with Platinum & Pemetrexed, in 67 pts with naïve #lungcancer with EGFR comm mut’s: the OPAL trial
▪️ORR: 90.9%
▪️mPFS: 31.0 months
▪️mOS: not reached
Carbo better then Cisp
🔗https://t.co/rggolCq6q6

Waiting for Ph3 FLAURA2, the idea of Chemo back in 1L…takes hold

In the other hand, the MARIPOSA trial evaluating Amivantamab plus lazertinib in the same setting, could be the alternative option, without chemo.

2023/24 will highlight a potential change in practice for the first-line of patients affected by NSCLC harbouring EGFR common alterations #LCSM